trending Market Intelligence /marketintelligence/en/news-insights/trending/mQoI77q65pXW4FK3BPHvFQ2 content esgSubNav
In This List

US FDA approves Teva's drug for chorea linked to Huntington's disease

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


US FDA approves Teva's drug for chorea linked to Huntington's disease

The U.S. FDA approved Teva Pharmaceutical Industries Ltd.'s AUSTEDO tablets for the treatment of chorea associated with Huntington's disease.

The FDA approval was based on results from a phase 3 study to assess the safety and efficacy of the drug in reducing chorea in patients with the disease.

Previously, the agency granted the drug an orphan drug designation in 2014.